242 related articles for article (PubMed ID: 31433302)
1. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
[TBL] [Abstract][Full Text] [Related]
2. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
4. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes.
Li J; Gordon SC; Rupp LB; Zhang T; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Lu M;
Aliment Pharmacol Ther; 2019 Mar; 49(5):599-608. PubMed ID: 30650468
[TBL] [Abstract][Full Text] [Related]
5. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M
J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994
[TBL] [Abstract][Full Text] [Related]
6. Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada.
Jeong D; Wong S; Karim ME; Manges AR; Makuza JD; Bartlett SR; Velásquez García HA; Luster D; Adu PA; Binka M; Yu A; Krajden M; Janjua NZ
Lancet Reg Health Am; 2024 Jan; 29():100658. PubMed ID: 38235369
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
8. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
Leone S; Prosperi M; Costarelli S; Nasta P; Maggiolo F; Di Giambenedetto S; Saracino A; Di Pietro M; Gori A
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1511-20. PubMed ID: 27272121
[TBL] [Abstract][Full Text] [Related]
9. Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C.
Honma Y; Shibata M; Morino K; Koya Y; Hayashi T; Ogino N; Kusanaga M; Oe S; Miyagawa K; Abe S; Tabaru A; Harada M
Dig Dis Sci; 2023 Feb; 68(2):685-698. PubMed ID: 36100828
[TBL] [Abstract][Full Text] [Related]
10. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.
Janjua NZ; Wong S; Darvishian M; Butt ZA; Yu A; Binka M; Alvarez M; Woods R; Yoshida EM; Ramji A; Feld J; Krajden M
J Viral Hepat; 2020 Aug; 27(8):781-793. PubMed ID: 32187430
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond.
Shengir M; Elgara M; Sebastiani G
World J Gastroenterol; 2021 May; 27(17):1959-1972. PubMed ID: 34007133
[TBL] [Abstract][Full Text] [Related]
12. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
Cacoub P; Desbois AC; Comarmond C; Saadoun D
Gut; 2018 Nov; 67(11):2025-2034. PubMed ID: 29703790
[TBL] [Abstract][Full Text] [Related]
13. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
[TBL] [Abstract][Full Text] [Related]
14. Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C.
Li J; Gordon SC; Zhou Y; Boscarino JA; Schmidt MA; Daida YG; Rupp LB; Trudeau S; Lu M;
Am J Gastroenterol; 2021 Mar; 116(3):576-583. PubMed ID: 33399360
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
16. [Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with pegylated interferon alfa-2a and ribavirin].
Fabri M; Ruzić M; Lendak D; Preveden T; Fabri I; Petrić V
Srp Arh Celok Lek; 2013; 141(5-6):320-4. PubMed ID: 23858800
[TBL] [Abstract][Full Text] [Related]
17. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
[TBL] [Abstract][Full Text] [Related]
18. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
19. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy.
Mazzaro C; Quartuccio L; Adinolfi LE; Roccatello D; Pozzato G; Nevola R; Tonizzo M; Gitto S; Andreone P; Gattei V
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835054
[TBL] [Abstract][Full Text] [Related]
20. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
